Severe acquired (secondary) high-density lipoprotein deficiency

Journal of Clinical Lipidology

Volumn 1, Issue 1, 2007, Pages 41-56

  Goldberg, Ronald B ^a   Mendez, Armando J ^a  

^a DIABETES RESEARCH INSTITUTE   (United States)

Author keywords

Secondary hypoalphalipoproteinemia; Severe HDL deficiency

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ANABOLIC AGENT; ANDROGEN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DEXAMETHASONE; FENOFIBRATE; FIBRIC ACID DERIVATIVE; FLUINDOSTATIN; GEMFIBROZIL; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; ISOTRETINOIN; METFORMIN; NANDROLONE DECANOATE; NICOTINIC ACID; OLANZAPINE; OXANDROLONE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PRAVASTATIN; PROBUCOL; PROTEINASE INHIBITOR; RAPAMYCIN; RECOMBINANT INTERLEUKIN 2; ROSIGLITAZONE; ROSUVASTATIN; STANOZOLOL; TESTOSTERONE; TRENBOLONE ACETATE; TRIACYLGLYCEROL; UNINDEXED DRUG;

ACQUIRED HIGH DENSITY LIPOPROTEIN DEFICIENCY; ARTICLE; BURN; CARDIOVASCULAR DISEASE; CRITICAL ILLNESS; DISEASE SEVERITY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; DYSLIPIDEMIA; GENE MUTATION; HEREDITY; HUMAN; HYPERTRIGLYCERIDEMIA; HYPOLIPOPROTEINEMIA; LIPOPROTEIN DEFICIENCY; LIPOPROTEIN METABOLISM; LIVER DISEASE; PARAPROTEINEMIA; PRIORITY JOURNAL; RISK FACTOR; SEPSIS; WEAKNESS;

EID: 34247849396     PISSN: 19332874     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacl.2007.02.003     Document Type: Article

References (77)

1. Rader D.J. Molecular regulation of HDL metabolism and function: implications for novel therapies. J Clin Invest 12 (2006) 3090-3100
2. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 285 (2001) 2486-2497
3. von Eckardstein A. Differential diagnosis of familial high density lipoprotein deficiency syndromes. Atherosclerosis 186 (2006) 231-239
4. Grundy S.M., Brewer Jr. H.B., Cleeman J.I., Smith Jr. S.C., Lenfant C.A.H.A.H., L., and a.B.I. Definition of metabolic syndrome: Report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation 109 (2004) 433-438
5. Despres J.P., Tremblay A., Perusse L., Leblanc C., and Bouchard C. Abdominal adipose tissue and serum HDL-cholesterol: association independent from obesity and serum triglyceride concentration. Int J Obes 12 (1988) 1-13
6. Laws A., and Reaven G.M. Insulin resistance and risk factors for coronary heart disease. Baillieres Clin Endocrinol Metab 7 (1993) 1063-1078
7. Chen Y.D., Jeng C.Y., and Reaven G.M. HDL metabolism in diabetes. Diabetes Metab Rev 3 (1987) 653-668
8. Hansen A.B., Lindegaard B., Obel N., Andersen O., Nielsen H., and Gerstoft J. HIV infection and high-density lipoprotein: the effect of the disease vs the effect of treatment. Metabolism 55 (2006) 90-95
9. Schaefer E.J., Levy R.I., Anderson D.W., Danner R.N., Brewer Jr. H.B., and Blackwelder W.C. Plasma-triglycerides in regulation of H.D.L.-cholesterol levels. Lancet 2 (1978) 391-393
10. Brinton E.A., Eisenberg S., and Breslow J.L. Human HDL cholesterol levels are determined by apoA-I fractional catabolic rate, which correlates inversely with estimates of HDL particle size. Effects of gender, hepatic and lipoprotein lipases, triglyceride and insulin levels, and body fat distribution. Arterioscler Thromb 14 (1994) 707-720
11. Rohrer L., Hersberger M., and von Eckardstein A. High density lipoproteins in the intersection of diabetes mellitus, inflammation and cardiovascular disease. Curr Opin Lipidol 15 (2004) 269-278
12. Vahlquist C. Effects of retinoids on lipoprotein metabolism. Curr Probl Dermatol 20 (1991) 73-78
13. Morrisett J.D., Abdel-Fattah G., and Kahan B.D. Sirolimus changes lipid concentrations and lipoprotein metabolism in kidney transplant recipients. Transplant Proc 35 3 suppl (2003) 143S-150S
14. Carr A., Samaras K., Chisholm D.J., and Cooper D.A. Pathogenesis of HIV-1-protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistance. Lancet 351 (1998) 1881-1883
15. Jockenhovel F., Bullmann C., Schubert M., et al. Influence of various modes of androgen substitution on serum lipids and lipoproteins in hypogonadal men. Metabolism 48 (1999) 590-596
16. Darney P.D. The androgenicity of progestins. Am J Med 16 1A (1995) 104S-110S
17. Weidmann P., de Courten M., Ferrari P., and Bohlen L. Serum lipoproteins during treatment with antihypertensive drugs. J Cardiovasc Pharmacol 22 suppl 6 (1993) S98-S105
18. Favari E., Zanotti I., Zimetti F., Ronda N., Bernini F., and Rothblat G.H. Probucol inhibits ABCA1-mediated cellular lipid efflux. Arterioscler Thromb Vasc Biol 24 (2004) 2345-2350
19. Mooradian A.D., Haas M.J., and Wong N.C. The effect of select nutrients on serum high-density lipoprotein cholesterol and apolipoprotein A-I levels. Endocr Rev 27 (2006) 2-16
20. Freeman D.J., Griffin B.A., Murray E., et al. Smoking and plasma lipoproteins in man: effects on low density lipoprotein cholesterol levels and high density lipoprotein subfraction distribution. Eur J Clin Invest 23 (1993) 630-640
21. Marik P.E. Dyslipidemia in the critically ill. Crit Care Clin 22 (2006) 151-159
22. Weidman S.W., Ragland J.B., and Sabesin S.M. Plasma lipoprotein composition in alcoholic hepatitis: accumulation of apolipoprotein E-rich high density lipoprotein and preferential reappearance of "light"-HDL during partial recovery. J Lipid Res 23 (1982) 556-569
23. Goldberg I.J. Lipoprotein metabolism in normal and uremic patients. Am J Kidney Dis 21 (1993) 87-90
24. Foger B., Trobinger G., Ritsch A., et al. Relationship of plasma cholesteryl ester transfer protein to HDL cholesterol. Studies in normotriglyceridemia and moderate hypertriglyceridemia. Arterioscler Thromb Vasc Biol 16 (1996) 1430-1436
25. Herbert P.N., and Henderson L.O. Plasma-triglycerides do not regulate high-density lipoprotein concentrations. Lancet 1 (1979) 1368-1370
26. Sprecher D.L., Hein M.J., and Laskarzewski P.M. Conjoint high triglycerides and low HDL cholesterol across generations. Analysis of proband hypertriglyceridemia and lipid/lipoprotein disorders in first-degree family members. Circulation 90 (1994) 1177-1784
27. Wendel M, Paul R, Heller AR. Lipoproteins in inflammation and sepsis. II. Clinical aspects. Intensive Care Med. 2006;Nov 9 [Epub ahead of print].
28. van Leeuwen H.J., Heezius E.C., Dallinga G.M., van Strijp J.A., Verhoef J., and van Kessel K.P. Lipoprotein metabolism in patients with severe sepsis. Crit Care Med 31 (2003) 1359-1366
29. Coombes E.J., Shakespeare P.G., and Batstone G.F. Lipoprotein changes after burn injury in man. J Trauma 20 (1980) 971-975
30. Badimon J.J., Fleming C.R., Patton J., and Mao S.J. Changes of plasma levels of apolipoproteins A-I, A-II, and B and their isoforms in patients with intestinal failure receiving long-term parenteral nutrition. Am J Clin Nutr 45 (1987) 414-422
31. Goldberg R.B., Weinberg R.B., and Landau R.L. Changes in plasma apolipoproteins A-I, A-II, and B, and lipoprotein cholesterol after jejunoileal bypass. Gastroenterology 84 (1983) 732-736
32. Hara T., Miller J.P., Gotto Jr. A.M., and Patsch J.R. Oxandrolone and plasma triglyceride reduction: effect on triglyceride-rich and high density lipoproteins. Artery 9 (1981) 328-341
33. Haffner S.M., Kushwaha R.S., Foster D.M., Applebaum-Bowden D., and Hazzard W.R. Studies on the metabolic mechanism of reduced high density lipoproteins during anabolic steroid therapy. Metabolism 32 (1983) 413-420
34. Sattler F.R., Schroeder E.T., Dube M.P., et al. Metabolic effects of nandrolone decanoate and resistance training in men with HIV. Am J Physiol Endocrinol Metab 283 (2002) E1214-E1222
35. Basaria S., Wahlstrom J.T., and Dobs A.S. Anabolic-androgenic steroid therapy in the treatment of chronic diseases. J Clin Endocrinol Metab 86 (2001) 5108-5117
36. Hartgens F., Rietjens G., Keizer H.A., Kuipers H., and Wolffenbuttel B.H. Effects of androgenic-anabolic steroids on apolipoproteins and lipoprotein (a). Br J Sports Med 38 (2004) 253-259
37. Tamai T., Nakai T., Yamada S., et al. Effects of oxandrolone on plasma lipoproteins in patients with type IIa, IIb and IV hyperlipoproteinemia: occurrence of hypo-high density lipoproteinemia. Artery 5 (1979) 125-143
38. O'Kane M.J., Lynch P.L., Callender M.E., and Trimble E.R. Abnormalities of serum apo A1 containing lipoprotein particles in patients with primary biliary cirrhosis. Atherosclerosis 131 (1997) 203-210
39. Claudel T., Sturm E., Duez H., et al. Bile acid-activated nuclear receptor FXR suppresses apolipoprotein A-I transcription via a negative FXR response element. J Clin Invest 109 (2002) 961-971
40. Sposito A.C., Vinagre C.G., Pandullo F.L., Mies S., Raia S., and Ramires J.A. Apolipoprotein and lipid abnormalities in chronic liver failure. Braz J Med Biol Res 30 (1997) 1287-1290
41. Kanel G.C., Radvan G., and Peters R.L. High-density lipoprotein cholesterol and liver disease. Hepatology 3 (1983) 343-348
42. Avgerinos A., Thalassinos N., Skliros P., et al. Plasma alpha-lipoprotein pattern and LCAT activity in acute viral hepatitis in children. Scand J Gastroenterol 19 (1984) 76-80
43. Chang L., Clifton P., Barter P., and Mackinnon M. High density lipoprotein subpopulations in chronic liver disease. Hepatology 6 (1986) 46-49
44. Katsuramaki T., Hirata K., Kimura Y., et al. Changes in serum levels of apolipoprotein A-1 as an indicator of protein metabolism after hepatectomy. Wound Repair Regen 10 (2002) 77-82
45. Kwong L.K., Ridinger D.N., Bandhauer M., et al. Acute dyslipoproteinemia induced by interleukin-2: lecithin:cholesteryl acyltransferase, lipoprotein lipase, and hepatic lipase deficiencies. J Clin Endocrinol Metab 82 (1997) 1572-1581
46. Staels B., and Fruchart J.C. Therapeutic roles of peroxisome proliferator-activated receptor agonists. Diabetes 54 (2005) 2460-2470
47. Teruel T., Hernandez R., Rial E., Martin-Hidalgo A., and Lorenzo M. Rosiglitazone up-regulates lipoprotein lipase, hormone-sensitive lipase and uncoupling protein-1, and down-regulates insulin-induced fatty acid synthase gene expression in brown adipocytes of Wistar rats. Diabetologia 48 (2005) 1180-1188
48. Schneider J.G., von Eynatten M., Schiekofer S., Nawroth P.P., and Dugi K.A. Low plasma adiponectin levels are associated with increased hepatic lipase activity in vivo. Diabetes Care 28 (2005) 2181-2186
49. Ebcioglu Z., Morgan J., Carey C., and Capuzzi D. Paradoxical lowering of high-density lipoprotein cholesterol level in 2 patients receiving fenofibrate and a thiazolidinedione. Ann Intern Med 139 (2003) W80
50. Sarker A., Semple R.K., Dinneen S.F., O'Rahilly S., and Martin S.C. Severe hypo-alpha-lipoproteinemia during treatment with rosiglitazone. Diabetes Care 27 (2004) 2577-2580
51. Gutschi L.M., Malcolm J.C., Favreau C.M., and Ooi T.C. Paradoxically decreased HDL-cholesterol levels associated with rosiglitazone therapy. Ann Pharmacother 40 (2006) 1672-1676
52. Senba H., Kawano M., and Kawakami M. Severe decrease in serum HDL-cholesterol during combination therapy of bezafibrate and pioglitazone. J Atheroscler Thromb 13 (2006) 263-264
53. Seber S., Ucak S., Basat O., and Altuntas Y. The effect of dual PPAR alpha/gamma stimulation with combination of rosiglitazone and fenofibrate on metabolic parameters in type 2 diabetic patients. Diabetes Res Clin Pract 71 (2006) 52-58
54. Boden G., Homko C., Mozzoli M., Zhang M., Kresge K., and Cheung P. Combined use of rosiglitazone and fenofibrate in patients with type 2 diabetes: prevention of fluid retention. Diabetes 56 (2007) 248-255
55. Normen L., Frohlich J., Montaner J., Harris M., Elliott T., and Bondy G. Combination therapy with fenofibrate and rosiglitazone paradoxically lowers serum HDL cholesterol. Diabetes Care 27 (2004) 2241-2242
56. Niemi M., Backman J.T., Granfors M., Laitila J., Neuvonen M., and Neuvonen P.J. Gemfibrozil considerably increases the plasma concentrations of rosiglitazone. Diabetologia 46 (2003) 1319-1323
57. Deng L.J., Wang F., and Li H.D. Effect of gemfibrozil on the pharmacokinetics of pioglitazone. Eur J Clin Pharmacol 61 (2005) 831-836
58. Chandler H.A., and Batchelor A.J. Ciprofibrate and lipid profile. Lancet 344 (1994) 128-129
59. Capps N.E. Lipid profiles on fibric-acid derivatives. Lancet 344 (1994) 684-685
60. McLeod A.J., Warren R.J., and Armitage M. Abnormal lipid profiles on fibrate derivatives. Lancet 347 (1996) 261
61. Collinson P.O., Hjelm C.J., and Canepo-Anson R. Paradoxical high-density lipoprotein reduction induced by fenofibrate and ciprofibrate. Ann Clin Biochem 33 (1996) 159-161
62. Oleesky D.A., and Mir M.A. Paradoxical high-density lipoprotein reduction induced by fibrate therapy. Ann Clin Biochem 34 (1997) 573-574
63. Murphy M.J., Packard C.J., and O'Reilly D.S. Fibrates and HDL cholesterol. Ann Clin Biochem 34 (1997) 114
64. Crook M.A., Lynas J., and Wray R. A paradoxical severe decrease in serum HDL-cholesterol after treatment with a fibrate. J Clin Pathol 53 (2000) 796-797
65. Murphy M.J., Duncan A., Vallance B.D., Packard C.J., and O'Reilly D.S. Iatrogenic profound hypoalphalipoproteinaemia: an unrecognised cause of very low HDL cholesterol. Postgrad Med J 71 (1995) 498-500
66. Vu-Dac N., Schoonjans K., Laine B., Fruchart J.C., Auwerx J., and Staels B. Negative regulation of the human apolipoprotein A-I promoter by fibrates can be attenuated by the interaction of the peroxisome proliferator-activated receptor with its response element. J Biol Chem 269 (1994) 31012-31018
67. Bovard-Houppermans S., Ochoa A., Fruchart J.C., and Zakin M.M. Fenofibric acid modulates the human apolipoprotein A-IV gene expression in HepG2 cells. Biochem Biophys Res Commun 198 (1994) 764-769
68. Beghin L., Capps N., Duhal N., Davies J., Staels B., and Luc G. Metabolism of apolipoproteins AI and AII in a patient with paradoxical reduction in high-density lipoprotein due to ciprofibrate. Ann Clin Biochem 36 (1999) 523-525
69. Mendez A.J., Goldberg R.B., Arnold P.I., and Schultz D.R. Acquired HDL deficiency associated with apolipoprotein A-I reactive monoclonal immunoglobulins. Arterioscler Thromb Vasc Biol 22 (2002) 1740-1741
70. Kadri N., Douville P., and Lachance P. Monoclonal paraprotein may interfere with the Roche direct HDL-C Plus assay. Clin Chem 48 (2002) 964
71. Pantanowitz L., Horowitz G.L., Upalakalin J.N., and Beckwith B.A. Artifactual hyperbilirubinemia due to paraprotein interference. Arch Pathol Lab Med 127 (2003) 55-59
72. Levy Y., Aviram M., Spira G., Tatarsky I., Brook G.J., and Carter A. Plasma cholesterol concentration and extra lipid band in monoclonal gammopathies. Postgrad Med J 60 (1984) 449-453
73. Hachem H., Favre G., Ghalim N., Puchois P., Fruchart J.C., and Soula G. Quantitative abnormalities of lipoprotein particles in multiple myeloma. J Clin Chem Clin Biochem 25 (1987) 675-679
74. Baca A., Haber R.J., Sujishi K., Frost P.H., and Ng V.L. Artifactual undetectable HDL-cholesterol with the Beckman synchron LX and vitros 950 assays temporally associated with a paraprotein. Clin Chem 50 (2004) 255-256
75. Berth M., and Delanghe J. Protein precipitation as a possible important pitfall in the clinical chemistry analysis of blood samples containing monoclonal immunoglobulins: 2 case reports and a review of the literature. Acta Clin Belg 59 (2004) 263-273
76. Tsai L.Y., Tsai S.M., Lee S.C., and Liu S.F. Falsely low LDL-cholesterol concentrations and artifactual undetectable HDL-cholesterol measured by direct methods in a patient with monoclonal paraprotein. Clin Chim Acta 358 (2005) 192-195
77. Murali M.R., Kratz A., and Finberg K.E. Case records of the Massachusetts General Hospital. Case 40-2006. A 64-year-old man with anemia and a low level of HDL cholesterol. N Engl J Med 355 (2006) 2772-2779